

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/815,573 03/22/01 DELUCA

H 1256-00721

THOMAS M. WOZNY  
ANDRUS, SCEALES, STARKE & SAWALL, LLP  
SUITE 1100  
100 EAST WISCONSIN AVENUE  
MILWAUKEE WI 53202-4178

HM12/0717

EXAMINER

JIANG, S

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 07/17/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

**Office Action Summary**

Application No.

09/815,573

Applicant(s)

DELUCA ET AL.

Examiner

Shaojia A. Jiang

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-7 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-7 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 4. 6) ☐ Other:

## DETAILED ACTION

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 and 4-6 are rejected under 35 U.S.C. 102(b) as being anticipated by DeLuca et al. (A, PTO-892).

DeLuca et al. discloses that a  $1\alpha$ -hydroxylated vitamin D such as  $1\alpha$ -hydroxy vitamin D<sub>3</sub>, within instant claim, with low phosphorus is useful in a method for prophylactically treating dairy cattle for parturient paresis. See abstract, col.2 lines 54-65, col.3 Example, and claims 1 and 3. DeLuca's teaching is inherent in a method of maintaining milk production in a dairy cow herein. See *Ex parte Novitski*, 26 USPQ 2d 1389. Thus, DeLuca et al. anticipates the claimed invention.

Claims 1, 4-5 and 7 are rejected under 35 U.S.C. 102(b) as being anticipated by DeLuca et al. (B, PTO-892).

DeLuca et al. discloses that a  $1\alpha$ -hydroxylated vitamin D such as  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub>, within instant claim, is useful in a method of treatment and prophylaxis for milk fever in dairy cattle. See abstract, col.2 lines 37-49, col.5 lines 10-19, and claims 1 and 6. DeLuca's teaching is inherent in a method of maintaining milk

Art Unit: 1617

production in a dairy cow herein. See *Ex parte Novitski*, 26 USPQ 2d 1389. Thus, DeLuca et al. anticipates the claimed invention.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 2-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over DeLuca et al. (A and B, PTO-892).

DeLuca et al. discloses that the oral administration to a dairy cow of a  $1\alpha$ -hydroxylated vitamin D such as  $1\alpha$ -hydroxy vitamin D<sub>3</sub> and  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub>, within instant claim, with low phosphorus is useful in a method of treatment and prophylaxis for milk fever in dairy cattle. See '312 abstract, col.2 lines 54-65, col.3 Example, and claims 1, 3, and 10; '446 abstract, col.2 lines 37-49, col.5 lines 10-19, and claims 1, 3, and 5.

DeLuca et al. do not expressly disclose the effective amount of  $1\alpha$ -hydroxylated vitamin D to be administered is 0.1 to 100  $\mu\text{g/kg}$  as a top dressing on the feed.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to motivated to optimize the effective amount of  $1\alpha$ -hydroxylated vitamin D to be administered to 0.1 to 100  $\mu\text{g/kg}$  as a top dressing on the feed.

Art Unit: 1617

One having ordinary skill in the art at the time the invention was made would have been motivated to optimize the effective amount of  $1\alpha$ -hydroxylated vitamin D to be administered to 0.1 to 100  $\mu\text{g/kg}$  as a top dressing on the feed because the optimization of amounts of active agents to be administered in the form of top dressing on the feed is considered well within the skill of artisan.

Thus the claimed invention as a whole is clearly prima facie obvious over the teachings of the prior art.


In view of the rejections to the pending claims set forth above, no claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (703) 305-1008. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

Shaojia A. Jiang, Ph.D.  
Patent Examiner, AU 1617  
July 6, 2001

  
MINNA MOEZIE, J.D.  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600